Harrow, Inc. stock dropped 50% post Q3 2024, but Q4 previews and FY 2025 projections signal growth potential. Click here to find out why HROW stock is a Hold.

NASHVILLE, Tenn., November 21, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the case of ImprimisRx, LLC v. OSRX ...

Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the fourth quarter and year ended December 31, 2022.

NASHVILLE, Tenn., March 24, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has ...

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutic ...